Cited 20 times in

Urgency to treat patients with chronic hepatitis C in Asia

DC Field Value Language
dc.contributor.author안상훈-
dc.date.accessioned2018-07-20T08:12:22Z-
dc.date.available2018-07-20T08:12:22Z-
dc.date.issued2017-
dc.identifier.issn0815-9319-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/160962-
dc.description.abstractChronic hepatitis C (CHC) infection poses a global healthcare burden, being associated with serious complications if untreated. The prevalence of hepatitis C virus (HCV) infection is highest in areas of Central, South, and East Asia; over 50% of HCV patients worldwide live in the region, where HCV genotypes 1b, 2, 3, and 6 are the most prevalent. Treatment outcomes for chronic hepatitis C vary by ethnicity, and Asian patients achieve higher sustained virologic response rates following interferon (IFN)-based therapy than non-Asians. However, low efficacy, poor safety profile, and subcutaneous administration limit the use of IFN-based therapies. Superior virologic outcomes have been observed with different classes of direct-acting antivirals (DAAs) alone or in combination, and several all-oral DAA regimens are available in Asia. These regimens have shown excellent efficacy and favorable tolerability in clinical trials, yet there is a need for further studies of DAAs in a real world context, particularly in Asia. Furthermore, IFN-free treatment may not be accessible for many patients in the region, and IFN-based regimens remain an option in some countries. There is a need to improve current clinical practices for HCV management in Asia, including effective screening, disease awareness, and prevention programs, and to further understand the cost-effectiveness of IFN-free regimens. The evolution of potent treatments makes HCV eradication a possibility that should be available to all patients. However, access to these therapies in Asian countries has been slow, primarily because of economic barriers that continue to present a hurdle to optimal treatment.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherBlackwell Scientific Publications-
dc.relation.isPartOfJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAntiviral Agents/therapeutic use*-
dc.subject.MESHAsia/epidemiology-
dc.subject.MESHGenotype-
dc.subject.MESHHealth Care Costs-
dc.subject.MESHHepacivirus/genetics-
dc.subject.MESHHepatitis C, Chronic/drug therapy*-
dc.subject.MESHHepatitis C, Chronic/economics-
dc.subject.MESHHepatitis C, Chronic/epidemiology-
dc.subject.MESHHepatitis C, Chronic/prevention & control-
dc.subject.MESHHumans-
dc.subject.MESHInterferons/therapeutic use*-
dc.subject.MESHPrevalence-
dc.titleUrgency to treat patients with chronic hepatitis C in Asia-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorJia‐Horng Kao-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorRong‐Nan Chien-
dc.contributor.googleauthorMong Cho-
dc.contributor.googleauthorWan‐Long Chuang-
dc.contributor.googleauthorSook‐Hyang Jeong-
dc.contributor.googleauthorChen‐Hua Liu-
dc.contributor.googleauthorSeung‐Woon Paik-
dc.identifier.doi10.1111/jgh.13709-
dc.contributor.localIdA02226-
dc.relation.journalcodeJ01417-
dc.identifier.eissn1440-1746-
dc.identifier.pmid28005275-
dc.identifier.urlhttps://onlinelibrary.wiley.com/doi/abs/10.1111/jgh.13709-
dc.subject.keywordAsia-
dc.subject.keywordHCV clinical trials-
dc.subject.keywordHCV treatment-
dc.subject.keywordclinical-
dc.subject.keywordhepatitis C-
dc.contributor.alternativeNameAhn, Sang Hoon-
dc.contributor.affiliatedAuthorAhn, Sang Hoon-
dc.citation.volume32-
dc.citation.number5-
dc.citation.startPage966-
dc.citation.endPage974-
dc.identifier.bibliographicCitationJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol.32(5) : 966-974, 2017-
dc.identifier.rimsid60856-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.